Key result
Anti-VEGF monoclonal antibodies significantly increased the risk of all-grade (RR 3.22; 95% CI 2.83-3.65; p<0.00001) and high-grade hypertension in cancer patients.
Why the study?
The study was conducted to fully investigate the risk of hypertension associated with anti-VEGF monoclonal antibodies in cancer patients.
Do anti-VEGF monoclonal antibodies increase the risk of hypertension in cancer patients?
Meta-Analysis (n=65,358)
Do anti-VEGF monoclonal antibodies increase the risk of hypertension in cancer patients?
The use of anti-VEGF monoclonal antibodies in cancer patients is associated with a significantly increased risk of both all-grade and high-grade hypertension.
Requires BP monitoring with anti-VEGF mAb therapy; confirms and quantifies hypertension risk across trials.
We performed a meta-analysis to fully investigate the hypertension of anti-VEGF mAbs in cancer patients. Databases were searched for randomized controlled trials (RCTs) treated with anti-VEGF mAbs till January 2021. The relevant RCTs in cancer patients treated with anti-VEGF mAbs were retrieved and the systematic evaluation was conducted. One hundred and five RCTs and 65358 patients were included. Our study suggests that anti-VEGF mAbs significantly increased the risks of all-grade (RR, 3.22; 95%CI, 2.83-3.65; p < 0.00001; I2=71%) and high-grade (RR, 6.15; 95%CI, 5.58-6.78; p < 0.00001; I2=48%) hypertension in cancer patients. Those risks may be dependent on drug type. Icrucumab did not association with an increased risk of hypertension. The RR of hypertension did not vary significantly according to the type of cancer, line of therapy, and treatment duration. The available data suggested that the use of anti-VEGF mAbs were associated with a significantly increased risk of hypertension.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2021) conducted a meta-analysis in cancer (n=65,358). anti-VEGF monoclonal antibodies vs. control was evaluated on all-grade hypertension (RR 3.22, 95% CI 2.83-3.65, p=< 0.00001). Anti-VEGF monoclonal antibodies significantly increased the risk of all-grade (RR 3.22; 95% CI 2.83-3.65; p<0.00001) and high-grade hypertension in cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: